Revision of PRECAUTIONS

Ivabradine hydrochloride

March 17, 2026

Therapeutic category

HCN channel blocker

Non-proprietary name

Ivabradine hydrochloride

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

<table>
<tr><th>Current</th><th>Revision</th></tr>
<tr><td>
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)
2.7 Patients receiving the following drugs: Preparations containing ritonavir, josamycin, itraconazole, clarithromycin, preparations containing cobicistat, voriconazole, ensitrelvir fumaric acid
10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with the following.)
<table>
<tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr>
<tr><td>Preparations containing ritonavir
Josamycin
Itraconazole
Clarithromycin
Preparations containing cobicistat
Voriconazole
Ensitrelvir fumaric acid</td><td>Excessive bradycardia may occur.</td><td>CYP3A-mediated metabolism of this drug is strongly inhibited, leading to an increase in the blood concentration of this drug.</td></tr>
</table>
</td><td>
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)
2.7 Patients receiving the following drugs: Preparations containing ritonavir, josamycin, itraconazole, clarithromycin, preparations containing cobicistat, voriconazole, ensitrelvir fumaric acid<u>, ceritinib</u>
10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with the following.)
<table>
<tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr>
<tr><td>Preparations containing ritonavir
Josamycin
Itraconazole
Clarithromycin
Preparations containing cobicistat
Voriconazole
Ensitrelvir fumaric acid
<u>Ceritinib</u></td><td>Excessive bradycardia may occur.</td><td>CYP3A-mediated metabolism of this drug is strongly inhibited, leading to an increase in the blood concentration of this drug.</td></tr>
</table>
</td></tr>
</table>